Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma

NCT00848640 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Sorafenib

Sponsor

Egyptian Foundation For Cancer Research